Transthyretin Amyloidosis – Global Drug Forecast and Market Analysis to 2029

2020-06-30
Price :
Published : Jun-2020
No. of Pages : 129

Transthyretin Amyloidosis – Global Drug Forecast and Market Analysis to 2029

Summary

Amyloidosis is a protein confirmation disorder that results in the build-up of insoluble amyloid proteins in tissues. This build-up can be fatal as it leads to disruption of organ systems and causes oxidative stress within the body. There are various forms of amyloidosis, each associated with the protein involved and the underlying cause of protein mis-folding. Amyloid aggregates affect different organs, most commonly the heart, kidney and liver whilst also affecting the peripheral, autonomic and gastro-intestinal (GI) systems. Most amyloidosis diagnoses are made later in life, with the average patient aged 65 at diagnosis.

Transthyretin Amyloidosis (ATTR) is caused by the transthyretin (TTR) protein and occurs in two forms, either hereditary or wild type. Majority of organ involvement in ATTR is found in the heart and nerves are also affected. Liver transplant is a plausible treatment option for patients with ATTR-m as the liver is the cause of the mutated TTR protein, therefore removing the source of the issue seems to work well. However, a process described as ‘seeding’ generally means that post-transplantation, the amyloid deposits eventually return due to the amyloid template left by pre-transplant mis-folding.

There are a number of unmet needs in the ATTR market, but drug treatment innovation is on the rise and diagnosis rates are expected to dramatically increase.

Key Highlights

– The main driver of the ATTR market expansion will be the approval and launch of the RNA interference therapeutics both ATTR polyneuropathy and ATTR cardiomyopathy. The approval of other pipeline agents of varying mechanism will also drive growth due to the current scarcity of the ATTR market.
– Another prominent contributor to sales growth the increase in diagnosed prevalence across the 7MM. This increase will be caused by improved understanding and awareness of the disease alongside campaigns by drug developers to increase genetic testing.
– The major global barrier for the ATTR market will be the annual cost of therapy for new pipeline drugs and the lack of options for advanced disease states, the stage at which majority of patients are diagnosed.
– The key market opportunities lie in addressing unmet needs through the development of efficacious therapies for clearing already deposited amyloid and increasing the number of therapies approved for ATTR cardiomyopathy.

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
– Develop business strategies by understanding the trends shaping and driving the global ATTR therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ATTR therapeutics market in future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track drug sales in the global ATTR therapeutics market from 2019-2029.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Scope

– Overview of ATTR, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized ATTR therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2019 and forecast for ten years to 2029.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ATTR therapeutics market.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
– Analysis of the current and future market competition in the global ATTR market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

– A number of new therapies of varying mechanisms will enter the ATTR market over the forecast period. What strengths do these drugs bring to the market?
– What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the ATTR market?
– The current late-stage ATTR pipeline consists of a number of novel mechanisms such as the RNA interference therapies, Alnylam’s Onpattro, vutrisiran, and AKCEA’s Tegsedi and AKCEA-TTR-LRx, and Eidos’ TTR stabilizer, AG10. Will the late-stage drugs make a significant impact on the ATTR market?
– Which of these drugs will have the highest peak sales at the highest CAGR, and why?
– The ATTR patient population is currently very small, and the disease is said to hold a falsely perceived rarity. However, the diagnosed patient population is expected to dramatically increase over the forecast period. Why will this occur?
– How will epidemiological changes impact the growth of the future market?

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Radiation Dose Management Market by Products & Services (Standalone Solutions, Integrated Solutions, Services), Modality (Computed Tomography, Nuclear Medicine), Application (Oncology, Cardiology, Orthopedic), End User (Hospitals) – Global Forecast to 2025

“Radiation dose management market is projected to grow at CAGR of 13.9% from 2020 to 2025” The global radiation dose management market is projected to reach USD 422.65 million by 2025 from USD 220.22 million in 2020, at a CAGR of 13.9% from 2020 to 2025. Growth in this market is driven by the increasing use of medical imaging modalities due to the rising incidence of chronic diseases, increasing concerns over radiation dose exposure, growth in the installed base of radiology equipment, and growing awareness on radiation dose management. On the other hand, the lack of standardized procedures and dose protocols for radiation dose management for healthcare organizations is a major market challenge. “Radiation dose management solutions segment to witness the highest growth during t......
$4950

Contract Manufacturing Service Agreements – Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion

Contract Manufacturing Service Agreements - Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion Summary This report is a brand new publication covering contract service agreements, across a range of different services and manufacturing scales. The number of contract service agreements secured serves as a primary indicator of a CMO's performance. Contract Manufacturing Service Agreements is critical for establishing an understanding of the overall CMO industry, the range of services provided and the features of some of the largest CMOs participating in the industry. This report gives an important expert quantitative analysis on the contract manufacturing industry. Findings are based on the industry's most comprehensive databases of the CMO industry (GlobalData'......
$4995

COVID-19 Pipeline of Small and Mid-Cap Bio/Pharma Companies – Coronavirus Disease 2019 Sector Forecast

COVID-19 Pipeline of Small and Mid-Cap Bio/Pharma Companies - Coronavirus Disease 2019 Sector Forecast Summary The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact Small and Mid Bio/Pharma Companies. Scope - This PowerPoint based report gives an important expert analysis on how the developement of vaccines and therapeutics for COVID-19 has been approached by Small and Mid Cap Bio/Pharma Companies. - Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis. Reasons to Buy - An overview of how Small and Mid Cap Bio/Pharma Companies have approached the developemnt of vaccines and therapeutics for the COVID-19 pandemic.......
$695

COVID-19 Impact on Inovio Pharmaceuticals Inc.

COVID-19 Impact on Inovio Pharmaceuticals Inc. Summary This PowerPoint based report gives an important expert analysis on how COVID-19 will affect Inovio Pharmaceuticals Inc. Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis. Scope - The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Inovio Pharmaceuticals Inc. performance. Inovio's focus is on DNA-based vaccines requiring a novel route of administration - Inovio's pipeline is most active in early-stage drug development - INO-4800 is Inovio's COVID-19 vaccine - Funding from different sources for INO-4800 Reasons to Buy - An overview of how Inovio Pharmaceuticals Inc. will......
$495

Hepatitis B Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)

Hepatitis B Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) Summary Hepatitis B Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on Hepatitis B Tests market for the year 2020 and beyond. Hepatitis B is a common cause of liver disease across the globe, and remains a major issue for most of the governments despite the fact that an effective vaccine has been available since 1982. The World Health Organization (WHO) recommends that all infants receive the hepatitis B vaccination and universal vaccinations have now been implemented in numerous count......
$7500

Hepatitis C Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)

Hepatitis C Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) Summary Hepatitis C Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on Hepatitis C Tests market for the year 2020 and beyond. Hepatitis C is a viral infection caused by hepatitis C virus (HCV). Hepatitis C virus is a blood borne virus that causes liver disease and can cause acute and chronic hepatitis. Infection may be caused through injection drug use, transfusion of unscreened blood products, unsafe injection practices, sexual contact and from infected mother to her baby. Diagnosis......
$7500

HIV Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)

HIV Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) Summary HIV Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on HIV Tests market for the year 2020 and beyond. HIV is an ongoing, global public health issue that remains a major priority for most governments. HIV tests are performed for two purposes: i) screening and diagnosis; or ii) monitoring of HIV-positive patients, particularly those undergoing antiretroviral therapy (ART). Screening of pregnant women for HIV is standard of care in most countries and considered to be a cost-effective st......
$7500

South Korea Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

South Korea Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report, "South Korea Healthcare, Regulatory and Reimbursement Landscape - CountryFocus". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in South Korea. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house an......
$1995

Taiwan Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Taiwan Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report, "Taiwan Healthcare, Regulatory and Reimbursement Landscape - CountryFocus". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in the Taiwan. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of the Taiwan. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house an......
$1995

Coronavirus Disease 2019 (COVID-19) – Epidemiology Analysis and Forecast (July 2020 Edition)

Coronavirus Disease 2019 (COVID-19) - Epidemiology Analysis and Forecast (July 2020 Edition) Summary Globally, the total confirmed cases of COVID-19 have reached over 17 million with over 667,000 deaths and 9,964,000 recoveries. The US continues to be the most affected country globally, with over 4.4 million cases. The US fell to ranking seventh globally in terms of per capita daily incident rates, however, the US is still ranked number one in terms of total daily incidence. South Africa reported over 7,200 new confirmed cases of COVID-19 yesterday and over 7,000 new confirmed cases of COVID-19 on Tuesday. These are the two lowest daily incident rates reported by South Africa since the beginning of July, however, South Africa still remains as ranking fourth in total daily incident rat......
$1995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy